マサチューセッツ州における慢性リンパ性白血病の臨床試験
マサチューセッツ州内の拠点で、慢性リンパ性白血病に関する33件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277231A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Dana Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT07061951A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/03更新 · NCT04588922Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第4相
18歳以上 · 全性別 · 2026/08/11更新 · NCT07426484Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
- Massachusetts General Hospital, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06849713Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
- Research Site, Boston
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/08/06更新 · NCT07024706A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
被験者募集中第1相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07020533A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Boston Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT06588478Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- 他2件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/07更新 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/04/24更新 · NCT00131014Understanding Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
被験者募集中観察研究
18歳以上 · 全性別 · 2026/04/24更新 · NCT04028531A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- UMass Memorial Medical Center /ID# 270023, Worcester
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
被験者募集中第2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/03/10更新 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Dana-Farber Cancer Institute, Boston
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Dana-Farber Cancer Institute, Boston
被験者募集中第4相
18歳以上 · 全性別 · 2026/03/02更新 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/11更新 · NCT06644183Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute /ID# 230061, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/09更新 · NCT04895436Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/21更新 · NCT06333262Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/01/07更新 · NCT06043674Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/15更新 · NCT07052695AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/10更新 · NCT05602363Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- South Shore Hospital, South Weymouth
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/05更新 · NCT05168930CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2025/07/17更新 · NCT04704323ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。